A detailed history of Klingman & Associates, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Klingman & Associates, LLC holds 1,659 shares of LLY stock, worth $1.27 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,659
Previous 1,578 5.13%
Holding current value
$1.27 Million
Previous $1.43 Million 2.87%
% of portfolio
0.09%
Previous 0.1%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$772.14 - $960.02 $62,543 - $77,761
81 Added 5.13%
1,659 $1.47 Million
Q2 2024

Jul 30, 2024

BUY
$724.87 - $909.04 $211,662 - $265,439
292 Added 22.71%
1,578 $1.43 Million
Q1 2024

May 01, 2024

BUY
$592.2 - $792.28 $5,329 - $7,130
9 Added 0.7%
1,286 $1 Million
Q4 2023

Jan 29, 2024

BUY
$525.19 - $619.13 $19,432 - $22,907
37 Added 2.98%
1,277 $744,000
Q3 2023

Oct 30, 2023

SELL
$434.7 - $599.3 $28,255 - $38,954
-65 Reduced 4.98%
1,240 $666,000
Q2 2023

Jul 31, 2023

BUY
$350.74 - $468.98 $75,759 - $101,299
216 Added 19.83%
1,305 $612,000
Q1 2023

May 03, 2023

BUY
$310.63 - $364.82 $310 - $364
1 Added 0.09%
1,089 $373,000
Q4 2022

Feb 03, 2023

BUY
$321.55 - $374.67 $8,360 - $9,741
26 Added 2.45%
1,088 $398,000
Q3 2022

Oct 28, 2022

BUY
$296.48 - $337.87 $9,783 - $11,149
33 Added 3.21%
1,062 $343,000
Q2 2022

Jul 27, 2022

SELL
$278.73 - $327.27 $16,723 - $19,636
-60 Reduced 5.51%
1,029 $334,000
Q1 2022

May 06, 2022

BUY
$234.69 - $291.66 $22,999 - $28,582
98 Added 9.89%
1,089 $312,000
Q4 2021

Jan 31, 2022

BUY
$224.85 - $279.04 $5,846 - $7,255
26 Added 2.69%
991 $274,000
Q3 2021

Nov 01, 2021

BUY
$221.6 - $272.71 $7,312 - $8,999
33 Added 3.54%
965 $223,000
Q2 2021

Jul 27, 2021

BUY
$180.55 - $233.54 $168,272 - $217,659
932 New
932 $214,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Klingman & Associates, LLC Portfolio

Follow Klingman & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Klingman & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Klingman & Associates, LLC with notifications on news.